InflaRx Hosts R&D Event Highlighting the Promise of INF904

INF904 CSU and HS clinical development program As previously disclosed, InflaRx will pursue two initial immuno-dermatology indications with INF904 in a single Phase 2a basket trial that is expected to begin by the end of 2024. The Phase 2a trial will be a multi- center, open-label study dosing 75 patients and evaluating multiple INF904 dosing regimens over 4 weeks of treatment in patients with moderate-to-severe CSU and moderate-to-severe HS. Outcome measures will be assessed via weekly visits to evaluate s ...